Special Sessions

SUNDAY, APRIL 19

Drug Development Track-Special Session 1
New Drugs on the Horizon

1:00 p.m.-3:00 p.m.
Co-Chairpersons: Steven K. Davidsen, Abbott Laboratories, Abbott Park, IL, and Emma M. Lees, Novartis Institutes for BioMedical Research, Emeryville, CA

MK-2206: A potent oral allosteric AKT inhibitor
Li Yan, Merck and Co., Inc., North Wales, PA

Development of an RNAi therapeutic targeting KSP and VEGF for the treatment of liver cancers
Dinah Sah, Alnylam Pharmaceuticals, Cambridge, MA

Identification of the p21-activated kinase inhibitor PF-3758309: A key effector of ras signaling
Brion W. Murray, Pfizer Global Research and Development, San Diego, CA

Special Session
AACR-FDA-NCI Cancer Biomarkers Collaborative Session: Towards a More Effective Biomarker Development Process – Right on the Path of the Critical Path

3:00 p.m-5:00 p.m.
Co-Chairpersons: William N. Hait, Ortho Biotech Oncology Research & Development, Raritan, NJ, Samir N. Khleif, National Cancer Institute, Bethesda, MD, and James H. Doroshow, National Cancer Institute, Bethesda, MD

Drug Development Track-Special Session 2
New Drugs on the Horizon

3:15 p.m-5:15 p.m.
Co-Chairpersons: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC, and Matthew A. Marx, Pfizer, Inc., San Diego, CA

Discovery and characterization of E6201: A potent natural product-inspired synthetic MEK1 inhibitor
Kenichi Nomoto, Eisai Research Institute, Andover, MA

MCS110: An anti-M-CSF antibody for the treatment of tumor-induced osteolysis
Nancy K. Pryer, Novartis Institutes for BioMedical Research, Emeryville, CA

Targeting the replication checkpoint with a potent and selective CHK1 inhibitor
David A. Parry, Schering-Plough Biopharma, Palo Alto, CA

Public Forum
Discovery to Delivery: A Public Forum about the Future of Cancer Research

4:30 p.m.-6:00 p.m.
Co-sponsored by AACR and Friends of Cancer Research

Moderator: Susan Dentzer, Health Affairs, Washington, DC

MONDAY, APRIL 20

Special Plenary Session
Spotlight on Breakthroughs in Cancer Research

8:00 a.m.-10:30 a.m.

Speakers to be announced. Featuring the latest clinical trial results and the most exciting new research.

Presidential Address

10:30 a.m.-11:30 a.m.

Cancer prevention: From molecules to practice
Raymond N. DuBois, UT M. D. Anderson Cancer Center, Houston, TX

A Dialogue with the Director of the National Cancer Institute

11:45 a.m.-12:45 p.m.

John E. Niederhuber, National Cancer Institute, Bethesda, MD
Raymond N. DuBois, President, AACR

AACR Annual Business Meeting

12:45 p.m.-2:00 p.m.

AACR/ASCO Session
AACR/ASCO Symposium: COX-2 and Cancer Treatment

2:30 p.m.-4:30 p.m.
Co-Chairpersons: Raymond N. DuBois, UT M. D. Anderson Cancer Center, Houston, TX, and Richard L. Schilsky, University of Chicago, Chicago, IL

COX-2 and cancer biology
Raymond N. DuBois, UT M. D. Anderson Cancer Center, Houston, TX

Overview of COX-2 as a target for cancer treatment
Richard L. Schilsky, University of Chicago, Chicago, IL

COX-2 in lung cancer: Rebirth of a target
Martin J. Edelman, University of Maryland, Baltimore, MD

COX-2 as a target for the prevention and treatment of colorectal cancer
Andrew Chan, Massachusetts General Hospital, Boston, MA

Early epigenetic and genetic events in carcinogenesis
Thea D. Tlsty, University of California School of Medicine, San Francisco, CA

A mouse model for COX-2 driven pancreatitis and pancreatic ductal adenocarcinoma
Susan M. Fischer, UT M. D. Anderson Cancer Center, Smithville, TX

TUESDAY, APRIL 21

Cancer Immunology Working Group Inaugural Scientific Session:
Immunopotentiating monoclonal antibodies as cancer therapeutics

5:30 p.m.-7:00 p.m.
Chairperson: Julie Y. Djeu, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Speakers to be announced

WEDNESDAY, APRIL 22

Special Session
AACR/International Liver Cancer Association Session: Pathogenesis and Treatment of Human Liver Cancer

8:00 a.m.-10:00 a.m.
Co-Chairpersons: Nelson Fausto, University of Washington School of Medicine, Seattle, WA, and Snorri S. Thorgeirsson, National Cancer Institute, Bethesda, MD

Identification of driver genes in human hepatocellular carcinoma
Snorri S. Thorgeirsson

Role of miRNAs in human hepatocellular carcinoma
Xin W. Wang, National Cancer Institute, Bethesda, MD

Tumor dormancy and oncogene addiction in hepatocellular carcinoma
Dean W. Felsher, Stanford University School of Medicine, Stanford, CA

BACK TO PROGRAM

Special Sessions

Drug Development Track-Special Session 1 New Drugs on the Horizon

Special Session AACR-FDA-NCI Cancer Biomarkers Collaborative Session: Towards a More Effective Biomarker Development Process – Right on the Path of the Critical Path

Drug Development Track-Special Session 2 New Drugs on the Horizon

Public Forum Discovery to Delivery: A Public Forum about the Future of Cancer Research

Special Plenary Session Spotlight on Breakthroughs in Cancer Research